Serotonin in the gastrointestinal tract

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 16, Issue 1, 2009, Pages 53-59

  Camilleri, Michael ^a,b  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

5 HT3 antagonist; ATI 7505; Genotype; Irritable bowel syndrome; Prucalopride; Reuptake; Serotonin transporter; TD 5108

Indexed keywords

ALOSETRON; ATI 7505; BUSPIRONE; CILANSETRON; NALTREXONE; NEUROTENSIN; OPIATE ANTAGONIST; PEPTIDE HISTIDINE METHIONINE; PLACEBO; PROLACTIN; PRUCALOPRIDE; RAMOSETRON; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; TD 5108; TEGASEROD; UNCLASSIFIED DRUG;

CONSTIPATION; CROHN DISEASE; DIARRHEA; DNA POLYMORPHISM; DRUG EFFICACY; DRUG POTENTIATION; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; GENETIC POLYMORPHISM; GENETIC REGULATION; GENOTYPE; HUMAN; IRRITABLE COLON; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

DEFECATION; EATING; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; HYDROXYINDOLEACETIC ACID; IRRITABLE BOWEL SYNDROME; MOOD DISORDERS; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGENTS;

EID: 58849165361     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32831e9c8e     Document Type: Review

References (55)

1. Dunlop SP, Coleman NS, Blackshaw PE, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3:349-357.
2. Coleman NS, Foley S, Dunlop SP, et al. Abnormalities of serotonin metabolism and their relation to symptoms in untreated celiac disease. Clin Gastroenterol Hepatol 2006; 4:874-881.
3. Houghton LA, Atkinson W, Whitaker RP, et al. Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003; 52:663-670.
4. Cremonini F, Camilleri M. Of actors, bolting horses, and drops in oceans! Gut 2003; 52:619-621.
5. Zuo XL, Li YQ, Yang XZ, et al. Plasma and gastric mucosal 5-hydroxytryptamine concentrations following cold water intake in patients with diarrhea-predominant irritable bowel syndrome. J Gastroenterol Hepatol 2007; 22:2330-2337.
6. Bellini M, Rappelli L, Blandizzi C, et al. Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron. Am J Gastroenterol 2003; 98:2705-2711.
7. Atkinson W, Lockhart S, Whorwell PJ, et al. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006; 130:34-43.
8. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in postdysenteric irritable bowel syndrome. Gut 2000; 47:804-811.
9. Miwa J, Echizen H, Matsueda K, Umeda N. Patients with constipation-predominant irritable bowel syndrome (IBS) may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habits. Digestion 2001; 63:188-194.
10. Minderhoud IM, Oldenburg B, Schipper ME, et al. Serotonin synthesis and uptake in symptomatic patients with Crohn's disease in remission. Clin Gastroenterol Hepatol 2007; 5:714-720.
11. Kerckhoffs AP, ter Linde JJ, Akkermans LM, Samsom M. Trypsinogen IV, serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients. Neurogastroenterol Motil 2008; 20:900-907.
12. Wang SH, Dong L, Luo JY, et al. Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome. World J Gastroenterol 2007; 13:6041-6047.
13. O'Mahony S, Chua AS, Quigley EM, et al. Evidence of an enhanced central 5HT response in irritable bowel syndrome and in the rat maternal separation model. Neurogastroenterol Motil 2008; 20:680-688.
14. Mayer EA, Berman S, Derbyshire SW, et al. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther 2002; 16:1357-1366.
15. Jarcho JM, Chang L, Berman SM, et al. Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT(3) receptor antagonist - a pilot study. Aliment Pharmacol Ther 2008; 28:344-352.
16. Hendrix TR, Atkinson M, Clifton JA, Ingelfinger FJ. The effect of 5-hydroxytryptamine on intestinal motor function in man. Am J Med 1957; 23:886-893.
17. Misiewicz JJ, Waller SL, Eisner M. Motor responses of human gastrointestinal tract to 5-hydroxytryptamine in vivo and in vitro. Gut 1966; 7:208-216.
18. Houghton LA, Atkinson W, Lockhart C, et al. Sigmoid-colonic motility in health and irritable bowel syndrome: a role for 5-hydroxytryptamine. Neurogastroenterol Motil 2007; 19:724-731.
19. von der Ohe MR, Camilleri M, Kvols LK, Thomforde GM. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med 1993; 329:1073-1078.
20. Di Stefano M, Miceli E, Mazzocchi S, et al. Effect of tegaserod on rectosigmoid tonic and phasic activity in constipation-predominant irritable bowel syndrome. Am J Gastroenterol 2007; 102:1720-1726.
21. von der Ohe MR, Camilleri M, Kvols LK. A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea. Gastroenterology 1994; 106:1184-1189.
22. von der Ohe MR, Hanson RB, Camilleri M. Serotonergic mediation of postprandial colonic tonic and phasic responses in humans. Gut 1994; 35:536-541.
23. Donowitz M, Binder HJ. Jejunal fluid and electrolyte secretion in carcinoid syndrome. Am J Dig Dis 1975; 20:1115-1122.
24. Borman RA, Burleigh DE. Heterogeneity of 5-HT receptors mediating secretion in the human intestine. Ann NY Acad Sci 1997; 812:224-225.
25. Grundy D. Signalling the state of the digestive tract. Auton Neurosci 2006; 125:76-80.
26. Gill RK, Pant N, Saksena S, et al. Function, expression, and characterization of the serotonin transporter in the native human intestine. Am J Physiol 2008; 294:G254-G262. Landmark article characterizing SERT in human intestinal and colonic epithelial cells.
27. Tack J, Broekaert D, Corsetti M, et al. Influence of acute serotonin reuptake inhibition on colonic sensorimotor function in man. Aliment Pharmacol Ther 2006; 23:265-274.
28. Chial HJ, Camilleri M, Burton D, et al. Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol 2003; 284:G130-G137.
29. Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003; 1:219-228.
30. Liu Q, Yang Q, Sun W, et al. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J Pharmacol Exp Ther 2008; 325:47-55. Novel class of compounds with potential to impact on 5-HT synthesis.
31. Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin re-uptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126:1657-1664.
32. Camilleri M, Andrews CN, Bharucha AE, et al. Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome. Gastroenterology 2007; 132:17-25. Robust appraisal of mucosal SERT in IBS, questioning prior observations.
33. Foxx-Orenstein A, Camilleri M, Gershon MD, et al. Alterations in intestinal serotonin expression in dyspepsia and irritable bowel syndrome. Gastroenterology 2007; 132:A72.
34. Spider R. Serotonin and GI clinical disorders. Neuropharmacology 2008; 55:1072-1080.
35. Colucci R, Blandizzi C, Bellini M, et al. The genetics of the serotonin transporter and irritable bowel syndrome. Trends Mol Med 2008; 14:295-304. Outstanding scholarly review of genetics of SERT.
36. Van Kerkhoven LA, Laheij RJ, Jansen JB. Meta-analysis: a functional polymorphism in the gene encoding for activity of the serotonin transporter protein is not associated with the irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26:979-986. Excellent meta-analysis of the 5HTTLPR genetics in IBS.
37. Kim HJ, Camilleri M, Carlson PJ, et al. Association of distinct alpha(2) adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut 2004; 53:829-837.
38. Park JM, Choi MG, Park JA, et al. Serotonin transporter gene polymorphism and irritable bowel syndrome. Neurogastroenterol Motil 2006; 18:995-1000.
39. Jarrett ME, Kohen R, Cain KC, et al. Relationship of SERT polymorphisms to depressive and anxiety symptoms in irritable bowel syndrome. Biol Res Nurs 2007; 9:161-169.
40. Grudell AB, Camilleri M, Carlson P, et al. An exploratory study of the association of adrenergic and serotonergic genotype and gastrointestinal motor functions. Neurogastroenterol Motil 2008; 20:213-219.
41. Camilleri M, Busciglio I, Carlson P, et al. Candidate genes and sensory functions in health and irritable bowel syndrome. Am J Physiol 2008; 295:G219-G225. Novel observation of association of 5HTTLPR genetics and visceral pain.
42. 3e receptor genetics and IBS.
43. Camilleri M, Atanasova E, Carlson PJ, et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002; 123:425-432.
44. 4 agonist.
45. 4 agonist.
46. 4 agonist and its effects on gastrointestinal transit.
47. Camilleri M, Manini M, McKinzie S, et al. Dose-related effects of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity, on gastrointestinal (GI) and colonic transit in healthy volunteers. Neurogastroenterol Motil 2008; 20 (Suppl 2):6.
48. Grider JR, Foxx-Orenstein AE, Jin JG. 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998; 115:370-380.
49. Foxx-Orenstein AE, Camilleri M, Szarka LA, et al. Does co-administration of a nonselective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial. Neurogastroenterol Motil 2007; 19:821-830.
50. 3 antagonist class of drugs.
51. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin Ther 2008; 30:884-901.
52. Matsueda K, Harasawa S, Hongo M, et al. A Phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 2008; 77:225-235.
53. Camilleri M. Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment? Neurogastroenterol Motil 2007; 19:77-84.
54. 3 antagonist and effects of baseline and postocclusion mesenteric flow.
55. Viramontes BE, Camilleri M, McKinzie S, et al. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96:2671-2676.